Submitted by endpointsnews6292 in business
Verge Genomics has secured its largest deal yet, linking up with AstraZeneca’s rare disease division Alexion in a deal worth up to $882 million. The San Francisco biotech said Friday morning that the four-year deal focuses on multiple undisclosed rare neurode…